Stockscreener 앱 받기
1.91
1.55%
-0.03
시간 외 거래:
1.90
-0.01
-0.52%
전일 마감가:
$1.94
열려 있는:
$1.95
하루 거래량:
2.64M
Relative Volume:
0.35
시가총액:
$343.97M
수익:
$850.00K
순이익/손실:
$-68.17M
주가수익비율:
-4.6404
EPS:
-0.4116
순현금흐름:
$-53.29M
1주 성능:
-7.73%
1개월 성능:
-12.79%
6개월 성능:
-70.16%
1년 성능:
-35.69%
1일 변동 폭
$1.86
$1.96
1주일 범위
$1.86
$2.225
52주 변동 폭
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.91 | 374.58M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-13 | 개시 | Craig Hallum | Buy |
| 2026-01-05 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Canaccord Genuity | Buy |
| 2025-12-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022 - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.080| - TradingKey
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Compass Therapeutics Inc. (CMPX) Balance Sheet - TradingKey
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX - TradingView
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Compass Therapeutics to present Phase 2/3 tovec... - Pluang
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity - Seeking Alpha
Compass Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesInvestor Earnings Call - DonanımHaber
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Clinical-Stage Focus - dars.gov.et
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Disciplined SpendingHigh Estimate Range - dars.gov.et
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic - The National Law Review
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to earnings forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics (CMPX) News Flow - Moomoo
Compass Therapeutics Adopts Second Amended and Restated Bylaws - The Globe and Mail
Compass Therapeutics Q1 2026 Earnings: Narrow EPS Beat Amid No Revenue; Stock Declines SlightlyAdjusted Earnings Analysis - dars.gov.et
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):